Copied
 
 
2022, DKK
30.06.2023
Bruttoresultat

25.164'

Primær drift

-74.809'

Årets resultat

-91.376'

Aktiver

2.249''

Kortfristede aktiver

585''

Egenkapital

596''

Afkastningsgrad

-3 %

Soliditetsgrad

27 %

Likviditetsgrad

40 %

Resultat
30.06.2023
Årsrapport
2022
30.06.2023
2021
29.06.2022
2020
16.04.2021
2019
21.04.2020
2018
22.05.2019
2017
26.03.2018
2016
29.03.2017
2015
18.03.2016
Nettoomsætning892.580.000932.545.000991.107.000881.616.000812.500.000867.662.000855.745.000800.654.000
Bruttoresultat25.164.000161.384.000246.394.000190.774.000121.357.000208.458.000546.474.000467.806.000
Resultat af primær drift-74.809.00096.348.000232.018.000137.995.00090.437.000171.343.000143.018.00092.941.000
Indtægter af kapitalandele (tilknyttede og associerede) 00000000
Finansielle indtægter134.0001.144.000758.000035.00033.0001.052.000210.000
Finansieringsomkostninger-14.083.000-29.513.000-26.667.000-25.358.000-18.952.000-27.109.000-8.534.000-9.869.000
Andre finansielle omkostninger00000000
Resultat før skat-113.589.00054.910.000198.463.000106.061.00061.649.000137.861.000131.433.00082.983.000
Resultat-91.376.00037.642.000155.411.00081.301.00045.844.000106.353.000100.073.00063.953.000
Forslag til udbytte00-130.000.000-160.000.0000000
Aktiver
30.06.2023
Årsrapport
2022
30.06.2023
2021
29.06.2022
2020
16.04.2021
2019
21.04.2020
2018
22.05.2019
2017
26.03.2018
2016
29.03.2017
2015
18.03.2016
Kortfristede varebeholdninger218.596.000198.750.000160.640.000187.633.000201.949.000151.218.000133.150.000130.483.000
Kortfristede tilgodehavender fra salg og tjenesteydelser 340.436.000209.474.000239.846.000171.281.000268.400.000196.465.000217.977.000148.082.000
Likvider26.399.00036.428.00062.977.0009.991.00084.553.0004.00056.0001.825.000
Kortfristede aktiver585.431.000444.652.000463.463.000368.905.000554.902.000347.687.000351.183.000280.390.000
Immaterielle aktiver og goodwill421.824.000372.548.000354.281.000295.837.000255.490.000166.022.000146.084.000131.477.000
Finansielle anlægsaktiver65.747.00079.711.00081.818.00084.301.00014.239.00016.660.00020.325.00022.308.000
Materielle aktiver1.176.473.0001.124.578.0001.098.822.0001.145.198.0001.179.400.0001.097.209.000999.409.000778.623.000
Langfristede aktiver1.664.044.0001.576.837.0001.534.921.0001.525.336.0001.449.129.0001.279.891.0001.165.818.000932.408.000
Aktiver2.249.475.0002.021.489.0001.998.384.0001.894.241.0002.004.031.0001.627.578.0001.517.001.0001.212.798.000
Aktiver
30.06.2023
Passiver
30.06.2023
Årsrapport
2022
30.06.2023
2021
29.06.2022
2020
16.04.2021
2019
21.04.2020
2018
22.05.2019
2017
26.03.2018
2016
29.03.2017
2015
18.03.2016
Forslag til udbytte00130.000.000160.000.0000000
Egenkapital596.345.000681.404.000770.126.000778.328.000895.989.000770.467.000659.605.000560.874.000
Hensatte forpligtelser139.981.000160.726.000150.464.000113.539.00099.777.00084.662.00077.848.00071.822.000
Langfristet gæld til banker00000000
Anden langfristet gæld36.898.00037.195.00036.135.00011.506.0000000
Leverandører af varer og tjenesteydelser84.883.00097.042.00061.653.00056.688.000109.684.00076.547.00062.068.00073.556.000
Kortfristede forpligtelser1.476.251.0001.142.164.000453.138.000406.174.000427.397.000195.408.000569.174.000382.173.000
Gældsforpligtelser1.513.149.0001.179.359.0001.077.794.0001.002.374.0001.008.265.000772.449.000779.548.000580.102.000
Forpligtelser1.513.149.0001.179.359.0001.077.794.0001.002.374.0001.008.265.000772.449.000779.548.000580.102.000
Passiver2.249.475.0002.021.489.0001.998.384.0001.894.241.0002.004.031.0001.627.578.0001.517.001.0001.212.798.000
Passiver
30.06.2023
Nøgletal
30.06.2023
Årsrapport
2022
30.06.2023
2021
29.06.2022
2020
16.04.2021
2019
21.04.2020
2018
22.05.2019
2017
26.03.2018
2016
29.03.2017
2015
18.03.2016
Afkastningsgrad -3,3 %4,8 %11,6 %7,3 %4,5 %10,5 %9,4 %7,7 %
Dækningsgrad 2,8 %17,3 %24,9 %21,6 %14,9 %24,0 %63,9 %58,4 %
Resultatgrad -10,2 %4,0 %15,7 %9,2 %5,6 %12,3 %11,7 %8,0 %
Varelagerets omsætningshastighed 4,1 4,7 6,2 4,7 4,0 5,7 6,4 6,1
Egenkapitals-forretning -15,3 %5,5 %20,2 %10,4 %5,1 %13,8 %15,2 %11,4 %
Payout-ratio Na.Na.83,6 %196,8 %Na.Na.Na.Na.
Gældsdæknings-nøgletal -531,2 %326,5 %870,1 %544,2 %477,2 %632,1 %1.675,9 %941,7 %
Soliditestgrad 26,5 %33,7 %38,5 %41,1 %44,7 %47,3 %43,5 %46,2 %
Likviditetsgrad 39,7 %38,9 %102,3 %90,8 %129,8 %177,9 %61,7 %73,4 %
Resultat
30.06.2023
Gæld
30.06.2023
Årsrapport
30.06.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 30.06.2023)
Information om virksomhedens regnskabsklasse:The annual report of Fertin Pharma A/S for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to large reporting class C entities.
Beretning
30.06.2023
Dato for ledelsens godkendelse af årsrapporten:2023-06-30
Oplysning om usædvanlige forhold:As per 31 December 2022, the companies liquidity ratio is below 100, which could indicate uncertainties around the companies liquidity. The company’s structural financing is anchored in PMI’s overall financial strategy and structure and hence based on intercompany loans from the PMI-group and funded through the parent company, Claudio Holdco A/S. As a part of this strategy, 1. 267 mDKK of the parent companies (Claudio Holdco A/S) short-term intercompany debt has been converted to a long-term intercompany loan as per 1 March 2023. In addition the Group has been granted a 1. 900 mDKK short-term intercompany facility to support the continues development of the company, incl. support to the overall PMI strategy. It is Managements assessment that the provided funding is sufficient to support the companies strategic business plans for the coming year.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Fertin Pharma A/S for the financial year 1 January - 31 December 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Business Activities Fertin Pharma A/S (“Fertin Pharma” or the “Company”) is a specialist Contract Development and Manufacturing Organization (“CDMO”) offering innovative, high-quality pharmaceutical and nutraceutical products for oral and intra-oral delivery. The Company’s current main product formats (“delivery systems”) are chewing gum, lozenges, powders, fast dissolvable tablets, Zapliq® chewables, and Zapliq® chewing gum. Fertin Pharma is the world’s largest independent developer and manufacturer of medicated chewing gum and has over recent years expanded into other specialized solid dosage oral and intra-oral delivery systems. The Company strives to develop innovative oral and intra-oral delivery systems that offer convenient and pleasurable delivery of active pharmaceutical ingredients (“APIs") and nutraceutical ingredients (“AIs") to patients and consumers. In 2022, the largest category continues to be high-quality chewing gum and lozenges systems applied within Nicotine Replacement Therapy (“NRT”) category. Following the current diversification strategy, Fertin Pharma is still utilizing its highly flexible delivery systems to grow business outside the NRT category, applying a wider range of APIs and AIs for OTC pharma and nutraceutical categories. The Company is headquartered in Vejle, Denmark, where it owns and operates US FDA and EU GMP approved R&D and manufacturing facilities. Furthermore, Fertin Pharma owns and operates commercial, R&D, and manufacturing facilities in India and Canada. In 2022 the company has merged with its sister-company, NordicCan A/S. The new entity continuous under Fertin Pharma A/S name. Business Review and Outlook In 2022, following the COVID-19 pandemic and customer’s related general hesitation in bringing new products to market, Fertin Pharma has realigned its focus in execution of the planned diversification of the business, aimed at growing the product and customer base across delivery platforms, API’s, and nutraceutical ingredients as well as geographies. During 2022, the business has still been challenged by delayed effects from COVID-19 and freight crisis, impacting sales of existing products across all categories as well as having resulted in customers postponing and - in some cases - cancelling their planned commercial launches of new products. Positively, we have – during 2022 – seen a material increase in customers interest in revitalising projects aimed at bringing new products to the market. The NRT category still forms the backbone of the business and has also proven to be the least affected by COVID-19 pandemic, compared to products in other categories more recently introduced to the market. Following PMI’s acquisition of Fertin Pharma, the Company has been highly engaged in supporting PMI’s strategy towards a smoke-free future. These added activities have materially impacted the Company’s cost structure. Apart from the effects described in the previous sections, the 2022 financial result has been materially affected by extraordinary inflation in energy and raw material prices, compared to previous years. Despite the negative effects from COVID-19 and extraordinary inflation, the Company has continued execute the planned investment program in R&D and CAPEX throughout 2022, supporting the diversification strategy and future growth. Moreover, initiatives have been implemented to manage the increased costs. Management expects the 2023 result to continue to be materially impacted by additional negative development in raw materials and energy prices. However, as a consequence of the implemented initiatives and stronger customer demand, management expects the 2023 result to improve beyond 2022. Revenue expected in the range of 900 to 1,100 mDKK.
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK